Products Affected - Description

• • Depo-Testosterone intramuscular injection, Pfizer, 100 mg/mL, 10 mL vial, NDC 00009-0347-02
  • Depo-Testosterone intramuscular injection, Pfizer, 200 mg/mL, 1 mL vial, 1 count, NDC 00009-0417-01
  • Depo-Testosterone intramuscular injection, Pfizer, 200 mg/mL, 10 mL vial, 1 count, NDC 00009-0417-02
  • Testosterone cypionate intramuscular injection, Eugia US, 100 mg/mL, 10 mL vial, 1 count, NDC 55150-0276-01
  • Testosterone cypionate intramuscular injection, Eugia US, 200 mg/mL, 10 mL vial, 1 count, NDC 55150-0278-01
  • Testosterone cypionate intramuscular injection, Hikma, 200 mg/mL, 10 mL vial, 1 count, NDC 00143-9726-01
  • Testosterone cypionate intramuscular injection, Pfizer, 100 mg/mL, 10 mL vial, 1 count, NDC 00409-6557-01

Reason for the Shortage

• • Cipla did not provide a reason for the shortage. The 200 mg/mL 10 mL vials were discontinued in 2022.
  • Eugia did not provide a reason for the shortage.
  • Hikma did not provide a reason for the shortage.
  • Padagis has testosterone cypionate injection available.
  • Pfizer has testosterone cypionate and Depo-Testosterone on shortage due to increased demand and manufacturing delays.
  • Sun Pharma discontinued testosterone cypionate in late-2023.

Available Products

• • Testosterone cypionate intramuscular injection, Cipla USA, 200 mg/mL, 1 mL vial, 1 count, NDC 69097-0802-32
  • Testosterone cypionate intramuscular injection, Eugia US, 200 mg/mL, 1 mL vial, 1 count, NDC 55150-0277-01
  • Testosterone cypionate intramuscular injection, Hikma, 200 mg/mL, 1 mL vial, 1 count, NDC 00143-9659-01
  • Testosterone cypionate intramuscular injection, Padagis, 200 mg/mL, 1 mL vial, 1 count, NDC 00574-0820-01
  • Testosterone cypionate intramuscular injection, Padagis, 200 mg/mL, 10 mL vial, 1 count, NDC 00574-0820-10
  • Testosterone cypionate intramuscular injection, Pfizer, 200 mg/mL, 1 mL vial, 1 count, NDC 00409-6562-01
  • Testosterone cypionate intramuscular injection, Pfizer, 200 mg/mL, 10 mL vial, 1 count, NDC 00409-6562-20

• • Eugia has testosterone cypionate 100 mg/mL 10 mL vials and 200 mg/mL 10 mL vials on intermittent back order and the company is releasing product as it becomes available.
  • Hikma has testosterone cypionate 200 mg/mL 10 mL vials on back order and the company estimates a release date of late-January 2026.
  • Pfizer has testosterone cypionate 100 mg/mL 10 mL vials available in limited supply with weekly releases.
  • Pfizer has Depo-Testosterone 100 mg/mL 10 mL vials and 200 mg/mL 1 mL and 10 mL vials on back order and the company cannot estimate a release date.

• • This drug is labeled for the treatment of delayed puberty and primary or hypogonadotropic hypogonadism.[1-2]

• • Testosterone cypionate injection is a schedule III controlled substance.[1-2]
  • Misuse of and dependence on testosterone cypionate may occur. Adverse events when this drug is misused include cardiac toxicity, hepatotoxicity, and psychiatric conditions such as depression, hallucinations, psychosis among others.[1]

• • Other testosterone dosage forms (eg, transdermal patch, gel) may be used for the treatment of hypogonadism while testosterone cypionate injection is on shortage.[3]
  • The choice of testosterone replacement therapy may depend on product availability, cost of therapy, and patient preference.[3]

• 1. Testosterone cypionate [prescribing information]. Berkeley Heights, NJ: Hikma Pharmaceuticals USA Inc; November 2021.
  2. Testosterone cypionate. Lexicomp Online. Wolters Kluwer Clinical Drug Information. Hudson, Ohio, USA. Accessed September 1, 2025.
  3. Thirumalai A, Berkseth KE, Amory JK. Treatment of hypogonadism: current and future therapies. F1000Research 2017. Updated January 24, 2017. doi: 10.12688/f1000research.10102.1